Shanghai Shyndec Pharmaceutical (600420.SH): Simvastatin Sodium Tablets (10mg) passed the generic drug consistency evaluation.

Shanghai Shyndec Pharmaceutical (600420.SH) announced recently that the company has received the approval notice for a drug supplementary application issued by the National Medical Products Administration. The approval is for the consistency evaluation of the generic drug quality and efficacy of Pravastatin Sodium Tablets (10mg). Pravastatin Sodium Tablets is a competitive inhibitor that can inhibit HMG-CoA reductase, thereby inhibiting the biosynthesis of cholesterol. It is indicated for patients with primary hypercholesterolemia or combined hypertriglyceridemia (types IIa and IIb), especially for those who cannot control their high lipid levels through diet restrictions, familial hypercholesterolemia. The company's Pravastatin Sodium Tablets in 10mg, 20mg, and 40mg formulations have passed the consistency evaluation, which will benefit the future market expansion and sales of the product.